Dr. Parbeer (Perry) Grewal

Dermatologist, Edmonton, AB

Dr. Parbeer Grewal completed his Bachelor of Science undergraduate degree at the University of Alberta with a specialization in Psychology and graduated with distinction. He completed his Doctorate of Medicine degree at the University of Alberta and graduated with Special Training in Research. He completed dermatology training at the University of Alberta and became a Fellow of the Royal College of Physicians and Surgeons of Canada and a board-certified Fellow of the American Academy of Dermatology.

Dr. Grewal is an Associate Clinical Professor within the University of Alberta’s Faculty of Medicine - Dermatology. In addition to working at Rejuvenation, he is a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital and the Misericordia Hospital. Dr. Grewal participated in over 60 clinical research trials for a multitude of dermatology conditions and medications. Additionally, Dr. Grewal serves on multiple national and international scientific advisory boards, is a distinguished peer reviewer for medical journals and has published both journal articles and book chapters in dermatology.

He has specific interests in psoriasis, acne, eczema, warts, skin cancers, rashes and moles. He offers a wide range of topical and systemic therapy along with surgical and aesthetic services.

1:20 PM - 1:50 PM

SAT Apr 29

Heads Up! A topline review of phase 3 clinical data in scalp psoriasis


After attending this program, attendees will be able to:

  1. Recognize current unmet needs and challenges in the management of scalp psoriasis
  2. Apply phase 3 trial data with tildrakizumab for the treatment of scalp psoriasis to clinical practice
  3. Identify patients with scalp psoriasis for whom tildrakizumab is appropriate

Session description:
Data from Phase 3 clinical trials prospectively evaluating currently available biologics in the treatment of scalp psoriasis are limited. In this session, Phase 3 trial data assessing the efficacy and safety of tildrakizumab in the treatment of moderate-to-severe psoriasis of the scalp will be presented. To demonstrate how the trial data can translate into the real-world, a patient case will be shared. The session will conclude with an opportunity for the audience to pose questions.